Aladar Szalay Sells 8,064 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $3.50, for a total value of $28,224.00. Following the transaction, the insider now owns 1,255,730 shares of the company’s stock, valued at approximately $4,395,055. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

GNLX stock opened at $3.32 on Friday. Genelux Co. has a fifty-two week low of $3.07 and a fifty-two week high of $40.98. The business’s 50-day moving average is $5.76 and its two-hundred day moving average is $10.90.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Equities research analysts forecast that Genelux Co. will post -0.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GNLX shares. Benchmark reissued a “speculative buy” rating and issued a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright dropped their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Amalgamated Bank raised its stake in shares of Genelux by 250.8% in the third quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after buying an additional 770 shares during the period. Tower Research Capital LLC TRC raised its stake in Genelux by 216.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after purchasing an additional 2,021 shares during the period. Barclays PLC raised its stake in Genelux by 516.4% during the 3rd quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after purchasing an additional 2,835 shares during the period. New York State Common Retirement Fund raised its stake in Genelux by 89.5% during the 3rd quarter. New York State Common Retirement Fund now owns 5,495 shares of the company’s stock valued at $135,000 after purchasing an additional 2,595 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in Genelux by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock valued at $87,000 after purchasing an additional 1,573 shares during the period. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.